

Author Contributions: Drs Mohanan and Malani had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: All authors.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Mohanan, Malani.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Mohanan, Malani.

Obtained funding: Mohanan, Acharya.

Administrative, technical, or material support: Mohanan, Krishnan, Acharya.

Supervision: Mohanan, Acharya.

Conflict of Interest Disclosures: Dr Malani reported receiving an award from Emergent Ventures used to fund research managers and assistants across a range of coronavirus disease 2019–related projects. Dr Krishnan reported that the Centre for Monitoring Indian Economy was paid to execute the survey from which data were used for this study. No other disclosures were reported.

Funding/Support: This study was funded by an Action Covid-19 Team grant awarded to IDFC Foundation (Mumbai, India).

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: We are grateful to the government of India (K. Vijay Raghavan, PhD, principal scientific advisor) and the government of Karnataka (Jawaid Akhtar, IAS, Pankaj Pandey, IAS, Selva Kumar, PhD, IAS, Gunjan Krishna, IAS, Karnataka Covid-19 Technical Advisory Committee, Manoj Kolla, Prakash Kumar, MD) for supporting and enabling this effort. We thank Gagandeep Kang, MD, PhD (Translational Health Science and Technology Institute), Vasanthapuram Ravi, PhD (National Institute of Mental Health and Neuro-Sciences), and Mahesh Vyas (Center for Monitoring Indian Economy) for timely advice and facilitating the project. We thank Reuben Abraham, Pritika Hingorani, and the IDFC Foundation team for supporting all aspects of the project. None of the individuals listed received any compensation for support or contributions to the study. We are thankful to Lipika Kapoor and Saloni Taneja for project management and to all team members from the Centre for Monitoring Indian Economy and the project team for undertaking challenging fieldwork during the epidemic. All diagnostic testing in the project was conducted at Aster Labs and Xcyton Labs.

1. Vyas M. Consumer Pyramids Household Survey: survey design and sample. Centre for Monitoring Indian Economy. Accessed December 13, 2020. <https://consumerpyramidsdx.cmie.com/kommon/bin/sr.php?kal=wkb>

2. Chaudhuri S, Thiruvengadam R, Chattopadhyay S, et al; DBT India Consortium for COVID-19 Research. Comparative evaluation of SARS-CoV-2 IgG assays in India. *J Clin Virol*. 2020;131:104609. doi:10.1016/j.jcv.2020.104609

3. Public Health England. Rapid assessment of Biomerieux ARGENE SARS-COV-2 R-GENE real-time detection kit. Accessed December 13, 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/921425/Rapid_assessment_Biomerieux_ARGENE_SARS-COV-2_R-GENE_Real-time_detection_kit.pdf

4. Rogan WJ, Gladen B. Estimating prevalence from the results of a screening test. *Am J Epidemiol*. 1978;107(1):71-76. doi:10.1093/oxfordjournals.aje.a112510

5. COVID19INDIA. Accessed December 13, 2020. <https://www.covid19india.org/>

6. Waghmare R, Gajbhiye R, Mahajan NN, Modi D, Mukherjee S, Mahale SD. Universal screening identifies asymptomatic carriers of SARS-CoV-2 among pregnant women in India. *Eur J Obstet Gynecol Reprod Biol*. 2021;256:503-505. doi:10.1016/j.ejogrb.2020.09.030

Association Between Changes in Social Distancing Policies in Ohio and Traffic Volume and Injuries, January Through July 2020

To minimize transmission of coronavirus disease 2019 (COVID-19), most US states in spring 2020 passed policies promoting social distancing through stay-at-home orders prohibiting nonessential travel.¹ While vehicle miles traveled in the US decreased by 41% in April 2020 compared with 2019,² the effect of this mobility decrease on motor vehicle

crashes (MVCs) is poorly understood. We estimated associations between COVID-19–related social distancing policies, traffic volume, and MVC-related outcomes in Ohio.

Methods | Our observational study compared MVCs and traffic volume data from two 7-month periods: January 1, 2020, through July 31, 2020, and January 1, 2019, through August 1, 2019 (accounting for the leap-year day in 2020). Motor vehicle crash data were obtained from the Ohio Department of Public Safety’s Electronic Crash Submission database.³ Traffic volume data were obtained from the Ohio Department of Transportation through permanent count stations positioned on interstate, state, and US routes.⁴

Three state-level policies demarked 4 study periods in 2020: period 1, January 1 through March 8; period 2, March 9 (state-of-emergency declaration) through March 22; period 3, March 23 (stay-at-home order) through May 11; and period 4, May 12 (retail reopening) through July 31. Mean daily counts were calculated and compared across periods for 3 types of crash-related outcomes: (1) number of people (motor vehicle drivers and passengers, pedestrians, motorcyclists, and bicyclists) involved in MVCs (MVC involvements), (2) number of people having any injuries in an MVC (MVC injuries), and (3) number of people having a severe or fatal injury in an MVC (MVC severe or fatal injuries), along with (4) traffic volume.


Daily interrupted time-series analyses with ordinary least-squares linear regression and Newey-West standard errors were used to estimate slope changes. All outcome variables were log transformed. Crash month, weekday or weekend occurrence, gasoline price, and unemployment rate were included in the analysis to control for seasonality and confounding. Statistical significance was defined as a 95% CI that excluded 0. As this study used publicly available, deidentified secondary data reported on an aggregated level, it did not undergo institutional review board review per institutional guidelines.

Results | From January 1 through July 31, 2020, MVCs were experienced by 284 128 individuals, with 27 809 having some level of injury and 3719 having severe injuries; there were 621 fatalities. These numbers were compared with MVCs during the 2019 study period, in which 382 098 individuals were involved in MVCs, 33 365 had some level of injury, 4243 had severe injuries, and there were 619 fatalities. When separated by period during 2020, all outcomes substantially declined during period 2 and reached their lowest levels directly following the stay-at-home order before gradually increasing through periods 3 and 4 (Figure).

Comparing slopes across periods, period 2 saw significantly larger daily changes than any other period of 2020 across all outcomes: for MVC involvements, -7.08% (95% CI, -8.31% to -5.82%); for MVC-related injuries, -5.08% (95% CI, -6.48% to -3.65%); for MVC-related severe or fatal injuries, -5.61% (95% CI, -8.19% to -2.95%); and for traffic volume, -4.07% (95% CI, -5.14% to -2.99%) (Table).

Relative to the same 2019 period, period 3 showed the largest difference: a -55% (95% CI, -62% to -49%) change in MVC

Figure. Daily Counts of Motor Vehicle Crash-Related Outcomes and Traffic Volume



The vertical dotted lines demarcate the study periods (P1-P4) in 2020. Period 1 was January 1 through March 8; period 2, March 9 (state-of-emergency declaration) through March 22; period 3, March 23 (stay-at-home order)

through May 11; and period 4, May 12 (retail reopening) through July 31. The x-axis is in reference to 2020 dates, accounting for the leap-year day. MVC indicates motor vehicle crash.

involvements, a -47% (95% CI, -54% to -40%) change in injuries, a -34% (95% CI, -47% to -21%) change in severe or fatal injuries, and a -44% (95% CI, -48% to -39%) change in traffic volume. In period 4, mean daily counts of MVC-related injuries and severe or fatal injuries approached 2019 levels.

Discussion | The period beginning with Ohio's state-of-emergency declaration was associated with the greatest daily percentage decrease in MVC involvements, injuries, and traffic volume compared with other state-level policies implemented during early stages of the pandemic. These findings coincided with behavior change likely associated with gubernatorial state-of-emergency declarations: schools suspended in-person classes, sporting events restricted spectators, and large gatherings were banned. A return to 2019 levels in the number of MVC injuries and severe or fatal injuries was observed in period 4, perhaps due to increased alcohol and cannabinoid use, speeding, harsh acceleration and braking events, and mobile

phone use observed among drivers following easing of COVID-19 lockdowns.^{5,6}

This study has limitations. As injury severity in Ohio crash reports was identified by police officers rather than medical professionals, nondifferential misclassification may exist. Additionally, the public's response to the pandemic may have been influenced by factors outside of policy (eg, media coverage). Also, generalizability beyond Ohio may be limited. Results were presented by various periods to facilitate cross-state comparisons.

As the pandemic continues, policy makers should consider the effects of lockdown and reopening policies on factors beyond COVID-19 infection, including MVC-related injuries and deaths.

Li Li, MS
 Lucas M. Neuroth, MPH
 Edward Valachovic, PhD
 David C. Schwebel, PhD
 Motao Zhu, PhD

Table. Mean Daily Counts and Changes in Motor Vehicle Crash Involvements, Injuries, Severe or Fatal Injuries, and Traffic Volume

Outcome and period ^a	Mean daily count (95% CI) ^b		Difference, % (95% CI) ^c		
	2019	2020	Period in 2020 vs same period in 2019 ^c	Period in 2020 vs previous period in 2020 ^c	2020 Daily % change (95% CI) ^d
Crash involvement					
Period 1	1759 (1634-1884)	1697 (1585-1810)	-3 (-13 to 6)	Not applicable	0.11 (-0.60 to 0.82)
Period 2	1555 (1421-1689)	1116 (907-1325)	-28 (-45 to -11)	-34 (-49 to -19)	-7.08 (-8.31 to -5.82)
Period 3	1767 (1670-1865)	788 (736-839)	-55 (-62 to -49)	-29 (-50 to -9)	0.97 (0.63 to 1.33)
Period 4	1881 (1817-1945)	1404 (1359-1449)	-25 (-30 to -21)	78 (69 to 87)	0.13 (-0.17 to 0.42)
Injuries					
Period 1	138 (128-148)	132 (125-140)	-4 (-13 to 5)	Not applicable	-0.23 (-0.89 to 0.44)
Period 2	127 (117-137)	100 (84-116)	-21 (-37 to -6)	-24 (-39 to -10)	-5.08 (-6.48 to -3.65)
Period 3	155 (146-163)	82 (76-88)	-47 (-54 to -40)	-18 (-36 to 0)	0.49 (-0.32 to 1.30)
Period 4	178 (173-184)	164 (158-170)	-8 (-12 to -3)	100 (90 to 110)	0.20 (-0.18 to 0.58)
Severe or fatal injuries					
Period 1	19 (17-20)	16 (15-17)	-14 (-25 to -3)	Not applicable	-0.41 (-1.21 to 0.40)
Period 2	18 (16-21)	16 (13-18)	-15 (-36 to 6)	-3 (-22 to 16)	-5.61 (-8.19 to -2.95)
Period 3	22 (20-24)	15 (13-16)	-34 (-47 to -21)	-7 (-28 to 14)	-0.27 (-1.43 to 0.90)
Period 4	27 (26-29)	28 (26-30)	4 (-6 to 13)	94 (75 to 113)	0.16 (-0.48 to 0.80)
Traffic volume^e					
Period 1	686 (653-720)	758 (728-788)	10 (4 to 17)	Not applicable	0.27 (-0.05 to 0.59)
Period 2	789 (731-848)	667 (572-763)	-15 (-30 to 0)	-12 (-26 to 2)	-4.07 (-5.14 to -2.99)
Period 3	821 (791-851)	463 (438-488)	-44 (-48 to -39)	-31 (-47 to -15)	0.50 (0.28 to 0.72)
Period 4	833 (810-857)	673 (652-695)	-19 (-23 to -15)	45 (38 to 52)	0.27 (0.09 to 0.45)

^a Between-year comparisons are adjusted to accommodate for the leap-year day in 2020. Period 1: January 1, 2020, through March 8, 2020, vs January 1, 2019, through March 9, 2019 (adjusting for the leap-year day in 2020). Period 2: March 9, 2020 (state-of-emergency declaration) through March 22, 2020, vs March 10, 2019, through March 23, 2019. Period 3: March 23, 2020 (stay-at-home order) through May 11, 2020, vs March 24, 2019, through May 12, 2019. Period 4: May 12, 2020 (retail reopening) through July 31, 2020, vs May 13, 2019, through August 1, 2019.

^b Mean number of outcomes per day were calculated from raw totals.

^c The 2-sample t test with unequal variance was used to calculate the difference

between periods. Differences were scaled by the reference period's point estimate to determine percentage difference.

^d Daily percent change was derived from interrupted time-series analysis using the slope of each period. Slope changes were estimated using Newey-West standard errors and daily interrupted time-series analyses with ordinary least-squares linear regression. All outcome variables were log transformed with a 7-day lag period. Models control for month, weekend vs weekday, weekly gasoline price, and monthly unemployment rate.

^e Indicates daily traffic volume divided by 10 000.

Author Affiliations: College of Public Health, The Ohio State University, Columbus (Li); The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio (Neuroth, Zhu); Department of Epidemiology and Biostatistics, State University of New York, Rensselaer (Valachovic); Department of Psychology, University of Alabama at Birmingham (Schwebel).

Accepted for Publication: December 11, 2020.

Corresponding Author: Motao Zhu, PhD, Center for Injury Research and Policy, The Abigail Wexner Research Institute at Nationwide Children's Hospital, 700 Children's Dr, Columbus, OH 43205-2664 (motao.zhu@nationwidechildrens.org).

Author Contributions: Dr Zhu had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Li, Neuroth, Zhu.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Li, Neuroth.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Li, Neuroth, Valachovic, Zhu.

Administrative, technical, or material support: Zhu.

Supervision: Zhu.

Conflict of Interest Disclosures: Dr Schwebel reported receipt of grants from the National Institutes of Health, Centers for Disease Control and Prevention (CDC), National Science Foundation, and US Department of Transportation (through the National Safety Council) and personal fees (consulting) from Procter & Gamble, Carney Badley Spellman, the University of Turku, Colorado State University, North Carolina

A&T State University, Cengage Hayward, the CDC, the European Science Foundation, Marshfield Clinics, Cineca, and The Ohio State University. No additional disclosures were reported.

Funding/Support: This research was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD; R01HD074594 [2013-2022]) and the National Institute on Aging (NIA; R01AG050581 [2016-2021]).

Role of the Funder/Sponsor: The NICHD and the NIA had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: Findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Ohio Department of Public Safety (ODPS) and the Ohio Department of Transportation (ODH).

Additional Contributions: We thank the ODPS and the ODH for providing motor vehicle crash data and traffic volume data.

1. Mervosh S, Lu D, Swales V. See which states and cities have told residents to stay at home. *New York Times*. Updated April 20, 2020. Accessed November 20, 2020. <https://www.nytimes.com/interactive/2020/us/coronavirus-stay-at-home-order.html>

2. Office of Highway Policy Information, US Federal Highway Administration. Traffic volume trends: April 2020. Accessed November 20, 2020. https://www.fhwa.dot.gov/policyinformation/travel_monitoring/20aprtvt/20aprtvt.pdf

3. Ohio Department of Public Safety. Crash Statistics System. Accessed September 1, 2020. <https://ohtrafficdata.dps.ohio.gov/crashstatistics/home>

4. Ohio Department of Transportation. Traffic Monitoring Management System. Accessed September 1, 2020. <https://odot.ms2soft.com/tcds/tsearch.asp?loc=odot>
5. Thomas FD, Berning A, Darrah J, et al. *Drug and Alcohol Prevalence in Seriously and Fatally Injured Road Users Before and During the COVID-19 Public Health Emergency*. National Highway Traffic Safety Administration Report DOT HS 813 018. Published October 2020. Accessed November 20, 2020. <https://rosap.nhtl.bts.gov/view/dot/50941>
6. Katrakazas C, Michelaraki E, Sekadakis M, Yannis G. A descriptive analysis of the effect of the COVID-19 pandemic on driving behavior and road safety. *Transportation Research Interdisciplinary Perspectives*. 2020;7. doi:10.1016/j.trip.2020.100186

COMMENT & RESPONSE

Use of e-Cigarettes for Smoking Cessation

To the Editor The role of electronic cigarettes (e-cigarettes) in smoking cessation is unclear. We are concerned about the interpretation of the recent trial by Dr Eisenberg and colleagues,¹ which demonstrated an increased rate of smoking cessation that did not persist at 24 weeks. Although this study did not demonstrate harm from e-cigarettes, neither did it demonstrate harm from combustible cigarettes. It is discordant to tout the potential safety of e-cigarettes from examining short-term outcomes in small numbers while acknowledging that harms from combustible cigarettes often take decades to manifest and occur only in a fraction of smokers. More than 50 years elapsed between the mass marketing of cigarettes in the late 19th century and realization of their association with lung cancer in the 1940s. As late as 1960, only one-third of US physicians thought the link between cigarettes and cancer had been established.² The mass marketing of e-cigarettes, which have been available for only 15 years, parallels that seen in prior decades with combustible cigarettes. In addition, the unclear messaging from physicians about potential harms of e-cigarettes also seems to parallel that of combustible cigarettes.

Recommending e-cigarettes as a promising intervention for smoking cessation is therefore premature. As currently used, e-cigarettes impede smoking cessation, resulting in 28% lower odds of quitting.³ Two possible explanations for the disparity between controlled studies and real-world results are volunteer bias, which occurs when participants who volunteer in a trial differ from the general public, and the Hawthorne effect, which occurs when the knowledge of being monitored alters participant behavior. Unlike varenicline or bupropion, e-cigarettes are freely available consumer products that require no monitoring from a physician. In comparison, nicotine patches became ineffective once they became available over the counter.⁴

It is frustrating that the success rate for curing tobacco abuse, a common and deadly habit, remains abysmally low. There is incontrovertible evidence demonstrating harms of e-cigarettes, and the risks are greater in the US, where regulation is limited.⁵ Whether those harms are greater than conventional therapies is currently unknown, and in the absence of close monitoring, e-cigarette use does not appear to actually reduce smoking. Until e-cigarettes demonstrate greater efficacy as a smoking cessation aid, and until the long-term risks are ascertained, physicians should refrain from recommend-

ing them as smoking cessation aids and from speculating that they are free from harm.

Michael J. Lanspa, MD
Denitza P. Blagev, MD
Sean J. Callahan, MD

Author Affiliations: Pulmonary and Critical Care Division, Intermountain Medical Center, Murray, Utah (Lanspa, Blagev); University of Utah Health, Salt Lake City (Callahan).

Corresponding Author: Michael J. Lanspa, MD, Division of Pulmonary and Critical Care Medicine, Intermountain Medical Center, 5121 S Cottonwood St, Murray, UT 84108 (michael.lanspa@gmail.com).

Conflict of Interest Disclosures: Drs Lanspa, Blagev, and Callahan are partially supported by the National Heart, Lung, and Blood Institute.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

1. Eisenberg MJ, Hébert-Losier A, Windle SB, et al; E3 Investigators. Effect of e-cigarettes plus counseling vs counseling alone on smoking cessation: a randomized clinical trial. *JAMA*. 2020;324(18):1844-1854. doi:10.1001/jama.2020.18889
2. Proctor RN. The history of the discovery of the cigarette-lung cancer link: evidentiary traditions, corporate denial, global toll. *Tob Control*. 2012;21(2):87-91. doi:10.1136/tobaccocontrol-2011-050338
3. Kalkhoran S, Glantz SA. e-Cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. *Lancet Respir Med*. 2016;4(2):116-128. doi:10.1016/S2213-2600(15)00521-4
4. Pierce JP, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. *JAMA*. 2002;288(10):1260-1264. doi:10.1001/jama.288.10.1260
5. Blagev DP, Harris D, Dunn AC, Guidry DW, Grissom CK, Lanspa MJ. Clinical presentation, treatment, and short-term outcomes of lung injury associated with e-cigarettes or vaping: a prospective observational cohort study. *Lancet*. 2019;394(10214):2073-2083. doi:10.1016/S0140-6736(19)32679-0

In Reply We agree with Dr Lanspa and colleagues that the role of e-cigarettes in smoking cessation is unclear. However, despite the surprising dearth of randomized clinical trials in this area,¹ many smokers have spontaneously turned to e-cigarettes as a potential method for quitting conventional cigarettes. Therefore, we believe that multiple studies in different settings are required to examine the efficacy and safety of e-cigarettes for smoking cessation. The adverse effects of smoking conventional cigarettes are well known.² Although the long-term effects of vaping e-cigarettes are unknown, most experts agree that, while their safety profile remains poorly understood, e-cigarettes are likely to be safer than conventional cigarettes.³ In our article,⁴ we acknowledge that the safety of e-cigarettes is an ongoing concern and recommend that, if adopted for smoking cessation, e-cigarettes should be used for a short period only.

Lanspa and colleagues also suggest that use of e-cigarettes may impede smoking cessation. However, several previous trials have suggested that e-cigarettes may be potentially useful for smoking cessation.⁵ Our trial adds to the evidence base in this area, specifically whether short-term use of e-cigarettes for 12 weeks can lead to longer-term cessation of conventional cigarette smoking. Importantly, most participants in our trial had previously tried to quit multiple times, and most had used other smoking cessation therapies, including varenicline and bupropion. First-line smoking cessation therapies,